Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2942954 | 0.85 | TRPV3 (0.42) | TRPV3TNK2PRMT5GPR119KDM4E | |
| SCHEMBL2907965 | 0.80 | PDE4B (0.48) | TNK2HDAC1HDAC2KDM4EMAPT | |
| SCHEMBL15985053 | 0.80 | TRPV3 (0.51) | TRPV3PRMT5GPR119KDM4EMAPT | |
| SCHEMBL3165154 | 0.79 | PDE4B (0.47) | TNK2GPR119HDAC1HDAC2KDM4E | |
| SCHEMBL28734092 | 0.78 | TRPV3 (0.48) | TRPV3PRMT5GPR119KDM4EMAPT | |
| SCHEMBL2943907 | 0.78 | TRPV3 (0.52) | TRPV3PRMT5GPR119KDM4EMAPT | |
| SCHEMBL25211356 | 0.78 | PDE4B (0.46) | TNK2HDAC1HDAC2KDM4EMAPT | |
| SCHEMBL25204517 | 0.77 | PDE4B (0.54) | TNK2HDAC1HDAC2KDM4EMAPT | |
| SCHEMBL25538690 | 0.77 | PDE4B (0.47) | TNK2HDAC1HDAC2KDM4EMAPT | |
| SCHEMBL17837770 | 0.77 | GPR119 (0.51) | TRPV3PRMT5GPR119KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9526731-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-27 | — | — | US | disclosed |
| US-9526731-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-27 | — | — | US | disclosed |
| US-9526731-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-27 | — | — | US | disclosed |
| EP-1807077-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-23 | — | — | EP | disclosed |
| EP-1807077-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-23 | — | — | EP | disclosed |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-02 | — | — | US | disclosed |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-02 | — | — | US | disclosed |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-02 | — | — | US | disclosed |
| US-8933091-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| US-8933091-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| WO-2007124369-A2 | METHOD OF INHIBITING C KIT KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| EP-1807077-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | disclosed |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007048088-A2 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| US-20060189623-A1 | Inhibitors of c-fms kinase | ILLIG CARL R | 2006-08-24 | — | — | US | disclosed |
| US-20060148812-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | disclosed |
| WO-2006047277-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189623-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | TRPV3 1084/4885TNK2 148/4885PRMT5 2788/4885 |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | FLT3, MCL1, CSF1R | TRPV3 4578/4885TNK2 156/4885PRMT5 483/4885 |
| US-20060148812-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | TRPV3 1084/4885TNK2 148/4885PRMT5 2788/4885 |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | FLT3, PLK1, PHKG1 | TRPV3 1052/4885TNK2 199/4885PRMT5 2652/4885 |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | KIT, CHUK, MAP3K13 | TRPV3 1091/4885TNK2 31/4885PRMT5 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.